seastarmedical.com - ICU Total Company Value-to-Revenue Ratio

The EV/Sales multiple history provided in GURU.Markets demonstrates the valuation dynamics of SeaStar Medical Holding, where the 732.72 metric indicates the asset's status. The current trend is linked to the rollout of B2B deliveries of selective cytoapheresis systems to US intensive care units. Revenues are based on the sale of SCD devices for kidney therapy, while an innovative method for clearing blood of pathogenic cells allows for the mitigation of severe organ failure.
Financial and market metric breakdowns for SeaStar Medical Holding Corp (ICU)

The EV/Sales trajectory reflects the market value of SeaStar Medical Holding, given its focus on developing blood purification systems for the therapy of critical inflammation. This metric correlates the total enterprise value with sales volume, excluding the impact of leverage, which allows investors to assess the efficiency of innovation capitalization and the risks of overpaying for future revenue growth.